Reconceptualizing podocyte damage in Fabry disease: new findings identify α-synuclein as a putative therapeutic target

Kidney Int. 2024 Feb;105(2):237-239. doi: 10.1016/j.kint.2023.08.023. Epub 2023 Sep 13.

Author

Dominique P Germain¹

Affiliation

¹ Division of Medical Genetics, University of Versailles-St Quentin en Yvelines, Montigny, France; French Reference Centre for Fabry Disease, Division of Medical Genetics, AP-HP Paris Saclay University, Garches, France. Electronic address: dominique.germain@uvsq.fr.

PMID: 37714429
DOI: 10.1016/j.kint.2023.08.023

No abstract available

Keywords: Fabry disease; chronic kidney disease; network medicine; podocytes; quantitative proteomics; synuclein.

MeSH terms

Fabry Disease* / diagnosis
Fabry Disease* / drug therapy
Humans
Podocytes*
Trihexosylceramides
alpha-Galactosidase / genetics
alpha-Galactosidase / therapeutic use
alpha-Synuclein / therapeutic use

Substances

alpha-Synuclein
alpha-Galactosidase
Trihexosylceramides